Skip to content
value.today
Rockwell Medical, Inc. logo

Rockwell Medical, Inc.

RMTI
$32 Mmarket cap on Oct 16, 2026-34.4% since Jan 2024
1D
+1.6%
Compare
World rank
#22,794
Revenue
$69 M
For year ending December-2025
Net income
$-5 M
-7.7% margin
SEC filing
Employees
—

Rockwell Medical, Inc. in brief

Rockwell Medical, Inc. is a listed company in the Pharmaceutical industry, based in Wixom, Michigan, USA. It was founded in 1996. Its market value was $32 M on 16 October 2026, which makes it the 22,794th largest listed company in the world and the 4,019th largest in the USA on this site. In the year to December 2025 it had sales of $69 M and a net loss of $5 M. Mark Strobeck is its chief executive. Its largest product and service lines by sales in 2025 were Concentrate Products Sales (100%) and License Fees (under 1%). By market, the largest shares of its 2025 sales came from USA (87%). Its shares trade under the symbol RMTI (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Rockwell Medical, Inc.

Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).

The company's primary customers are dialysis providers.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Rockwell Medical, Inc. timeline

5 events, 1995–2024
  1. 1995
  2. 🏁
    · approximate
    Founded
  3. 1997
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 1998
  6. 🔔
    · approximate
    Initial public offering on Nasdaq as RMTI
  7. 2012
  8. ✎
    Renamed Rockwell Medical, Inc.
    Formerly Rockwell Medical Technologies Inc.
  9. 2024
  10. 💰
    Record revenue of $101 million
    FY2024, the highest of the 8 years on record.

Events of Rockwell Medical, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$41 M$82 M$122 M$163 M2020202120222023202420252026

World rank over time

▼ down 5,715 places since 2020
2020-01-01: #17098#17,09820202021-01-01: #18509#18,50920212022-01-07: #27483#27,48320222022-12-25: #31164#31,16420222023-07-30: #21597#21,59720232024-01-05: #24961#24,96120242026-03-08: #11453#11,45320262026-08-01: #20921#20,92120262026-10-14: #22954#22,95420262026-10-16: #22813#22,8132026

Rank in USA: #3,436 (Jan 2020) · #3,735 (Jan 2021) · #5,048 (Jan 2022) · #5,529 (Dec 2022) · #4,213 (Jul 2023) · #4,068 (Jan 2024) · #2,225 (Mar 2026) · #3,878 (Aug 2026) · #4,008 (Oct 2026) · #4,022 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
n/m (loss)
Price / sales (TTM)
0.4×
Price / book
0.9×
Free cash flow yield
-3.7%
Net margin (TTM)
-7.8%
Operating margin
-6.8%
Return on equity
-15.3%
Liabilities / assets
35.3%
Net debt
$-2M
Revenue growth
-31.8%
R&D / revenue
0.0%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $63M, net income $-32M$63MFY18Fiscal year ending Dec 2019: revenue $61M, net income $-34M$61MFY19Fiscal year ending Dec 2020: revenue $62M, net income $-31M$62MFY20Fiscal year ending Dec 2021: revenue $62M, net income $-33M$62MFY21Fiscal year ending Dec 2022: revenue $73M, net income $-19M$73MFY22Fiscal year ending Dec 2023: revenue $84M, net income $-8M$84MFY23Fiscal year ending Dec 2024: revenue $101M, net income $-0M$101MFY24Fiscal year ending Dec 2025: revenue $69M, net income $-5M$69MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$69M-31.8%$-5M$-5M-7.7%
Dec 2024$101M+21.4%$1M$-0M-0.5%
Dec 2023$84M+14.8%$-7M$-8M-10.1%
Dec 2022$73M+17.6%$-17M$-19M-25.7%
Dec 2021$62M-0.4%$-30M$-33M-52.8%
Dec 2020$62M+1.5%$-28M$-31M-49.7%
Dec 2019$61M-3.3%$-35M$-34M-55.7%
Dec 2018$63M—$-32M$-32M-50.7%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-1M$1M$-1M$-0.15—
Dec 2024$4M$1M$3M$-0.03—
Dec 2023$-9M$0M$-10M$-0.37—
Dec 2022$-17M——$-1.31—
Dec 2021$-34M——$-3.83—
Dec 2020$-30M——$-0.41—
Dec 2019$-27M——$-0.56—
Dec 2018$-20M——$-0.61—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$73M
Net income, trailing 12 months
$-6M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $25M, net income $-1M$25MDec ’24Three months to Mar 2025: revenue $19M, net income $-2M$19MMar ’25Three months to Jun 2025: revenue $16M, net income $-1M$16MJun ’25Three months to Sep 2025: revenue $16M, net income $-2M$16MSep ’25Three months to Dec 2025 (from the annual report): revenue $18M, net income $-1M$18MDec ’25Three months to Mar 2026: revenue $17M, net income $-2M$17MMar ’26Three months to Jun 2026: revenue $18M, net income $-1M$18MJun ’26Three months to Sep 2026: revenue $19M, net income $-2M$19MSep ’26

Latest quarter to Sep 2026: revenue $19M (+20.0% on a year earlier), net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Rockwell Medical, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$69 M
Operating income
$-5 M
Net income
$-5 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$57 M
Total liabilities
$20 M
Total equity
$37 M

As of December-2025

Top 27 institutional investors in Rockwell Medical, Inc.#

As of Sep 30, 2026
27 institutions held 295,936 shares (about 7.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 7.2%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Rockwell Medical, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC120,407New2.99%$1 MNov 13, 2026
2Geode Capital Management, LLC39,703New0.99%$0 MNov 6, 2026
3Renaissance Technologies LLC35,864New0.89%$0 MNov 12, 2026
4Vanguard Fiduciary Trust Co23,266New0.58%$0 MNov 13, 2026
5Wealthspire Advisors, LLC15,183New0.38%$0 MNov 13, 2026
6BlackRock, Inc.14,173New0.35%$0 MNov 13, 2026
7Jane Street Group, LLC11,417New0.28%$0 MNov 12, 2026
8Gsa Capital Partners LLP10,568New0.26%$0 MNov 16, 2026
9State Street Corp10,089New0.25%$0 MNov 12, 2026
10UBS Group AG10,009New0.25%$0 MNov 10, 2026
11Harbour Investments, Inc.1,749-20,116 (-92.00%)0.04%$0 MNov 9, 2026
12Vanguard Global Advisers, LLC1,057New0.03%$0 MNov 13, 2026
13Wells Fargo & Company/mn998New0.02%$0 MNov 16, 2026
14Pinnacle Financial Group, Inc.700—0.02%$0 MNov 16, 2026
15Morgan Stanley367New0.01%$0 MNov 13, 2026
16Nuveen, LLC74New0.00%$0 MNov 10, 2026
17IFG Advisory, LLC67New0.00%$0 MNov 9, 2026
18Tower Research Capital LLC (TRC)66New0.00%$0 MNov 16, 2026
19Kovack Advisors, Inc.58New0.00%$0 MNov 13, 2026
20William Mack & Associates, Inc.30New0.00%$0 MOct 27, 2026
21Osaic Holdings, Inc.27New0.00%$0 MNov 12, 2026
22Jones Financial Companies Lllp25New0.00%$0 MNov 13, 2026
23Fifth Third Bancorp16New0.00%$0 MNov 5, 2026
24Compass Financial Management LLC120 (0.00%)0.00%$0 MOct 30, 2026
25SBI Securities Co., Ltd.5-62 (-92.54%)0.00%$0 MOct 22, 2026
Show all 27: investors 26 to 27
Institutional investors 26 to 27 in Rockwell Medical, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Jpmorgan Chase & Co3New0.00%$0 MNov 12, 2026
27Farther Finance Advisors, LLC3New0.00%$0 MOct 8, 2026

Mutual funds holding Rockwell Medical, Inc.#

7 funds hold shares worth $1 M. Since their previous reports 3 added shares and 3 sold, selling $0 M net.
Mutual funds holding Rockwell Medical, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.844,926$0 M—<0.01%+6.1%Jun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.359,156$0 M—<0.01%−0.4%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC218,753$0 M—<0.01%+16%May 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC52,325$0 M—<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC49,481$0 M—<0.01%+3.2%May 31, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.25,806$0 M—<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC17,380$0 M—<0.01%no changeMay 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 7 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Rockwell Medical, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$12 K
3 sales, 3 insiders
Net, 12 months
-$12 K
open market only
Insiders on file
39
since
$94 K-$70 K$0Oct 2024: bought $0 (0 trades), sold $12 K (2 trades)Oct 24Nov 2024: bought $0 (0 trades), sold $70 K (2 trades)Jan 2025: bought $0 (0 trades), sold $7 K (2 trades)Jan 25Apr 2025: bought $94 K (30 trades), sold $12 K (3 trades)Jul 2025: bought $0 (0 trades), sold $9 K (3 trades)JulOct 2025: bought $0 (0 trades), sold $13 K (4 trades)Nov 2025: bought $0 (0 trades), sold $4 K (1 trades)NovJan 2026: bought $0 (0 trades), sold $3 K (2 trades)Oct 2026: bought $0 (0 trades), sold $8 K (1 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
Rockwell Medical, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Mark StrobeckPresident and CEO, DirectorSell10b5-1 plan-1,000$8.420$8 K61,349Form 4
filed Joseph H. DawsonDirectorGrant or award+9,633——12,133Form 4
filed Jesse NeriSVP and CFOGrant or award+15,000——27,239Form 4
filed Mark StrobeckPresident and CEO, DirectorGrant or award+30,000——62,349Form 4
filed Timothy CholeSVP and CCOGrant or award+15,000——27,285Form 4
filed Megan C. TimminsEVP, CLO & SecretaryGrant or award+15,000——31,240Form 4
filed Robert S. RadieDirectorGrant or award+9,633——23,985Form 4
filed Joan LauDirectorGrant or award+9,633——20,944Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Rockwell Medical, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
35,533
1.44 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-10 reverse split ; 1-for-10 reverse split

Trading halts

  • 2026-06-30 23:50 UTC, code T3, resumed 13:00 UTC

Fails to deliver

  • : 29 shares at $7.98
  • : 1,306 shares at $7.85
  • : 330 shares at $8.55
  • : 799 shares at $8.63
  • : 199 shares at $8.37

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Rockwell Medical, Inc. scorecard#

Passes 7 of the 22 checks that could be worked out: strongest in financial health (3 of 5), weakest in growth (1 of 6). Fiscal year 2025; market cap of Oct 16, 2026.

  • Valuation2 of 5
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.9×Price to book 0.9× against Pharmaceutical's median of 3.2×.
    • ✓Price to sales below its peers' median0.4×Price to sales 0.4× against Pharmaceutical's median of 3.5×.
    • ✗Free cash flow yield above 5%-3.7%Free cash flow is -3.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 6
    • ✗Revenue grew in the newest year-31.8%Revenue down 31.8% in fiscal 2025.
    • ✗Revenue up more than 5% a year over three years-1.6%-1.6% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median-1.6%-1.6% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✗Earnings per share grew in the newest year-0.15 vs -0.03Diluted EPS -0.15 in fiscal 2025 against -0.03 the year before (report's currency).
    • ✓Net income higher than five years earlier-$5 M-$5 M in fiscal 2025 against -$31 M in 2020.
    • ✗Revenue rose in at least four of the last five years3 of 5Revenue rose in 3 of the five years to fiscal 2025.
  • Profitability1 of 5
    • ✗Profitable in the newest year-$5 MNet income -$5 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✗Operating margin above its peers' median-6.8%-6.8% against Pharmaceutical's median of 1.8% (74 companies).
    • ✗Return on equity above 15%-15.3%-15.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-6.8%-6.8% in fiscal 2025 against -23.0% in 2022.
  • Financial health3 of 5
    • ✓Short-term assets cover short-term liabilities4.0×Current ratio 3.98 at the end of fiscal 2025.
    • ✓Debt below equity0.2×Debt to equity 0.24 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $2 M at the end of fiscal 2025.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-7.38Z-score -7.38 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year15.8%Diluted shares up 15.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Rockwell Medical, Inc.'s statements, beside the median of Pharmaceutical.

Rockwell Medical, Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-6.8%1.8%
Net margin-7.7%-1.5%
Return on equity-15.3%-0.9%
Revenue growth, 3 years a year-1.7%2.5%
Revenue growth-31.8%7.3%
Debt to equity0.24×0.66×

3of 9on the Piotroski tests of financial strength

  • Revenue fell 31.8% against the year before.
  • Net loss of $5 million, the 17th loss-making year in a row.
  • Free cash flow was negative: -$1 million.
  • The share count rose 15.8% in the year.

Rockwell Medical, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Rockwell Medical, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue691018473626261r635753
Cost of revenue58847569645958r655447
Gross profit12178.74.1−2.42.72.8r−1.63.76.8
Research and development00.01.13.16.87.16.9r5.66.35.8
Selling, general and administrative———————232321
Selling and marketing2.42.72.12.15.77.99.1r1.0——
General and administrative14141216151621r22——
Operating income−4.70.6−6.7−17−30−28−35r−32−26−20
Interest and finance income——0.20.00.00.20.4——0.8
Interest expense and finance costs1.11.32.31.92.41.90.0———
Net interest income——————0.40.5r0.8—
Other non-operating income (expense)−0.6−1.1−1.8−1.9−2.3−2.50.4r0.30.0—
Income before tax−5.3−0.5−8.4—————−26−19
Income tax0000000000.4
Net income attributable to shareholders−5.3−0.5−8.4−19−33−31−34r−32−26−20
Earnings per share, basic-0.15-0.03-0.37-1.31r-3.83r-0.41-0.56-0.61-0.51-0.39
Earnings per share, diluted-0.15-0.03-0.37-1.31r-3.83r-0.41-0.56-0.61-0.51-0.39
Shares, weighted average (basic)36312314r8.5r76——5151
Shares, weighted average (diluted)36312314r8.5r7661535151
Balance sheet
Cash and cash equivalents11169.010134912r238.417
Short-term investments145.92.0119.210.014r11——
Receivables8.18.3116.35.94.24.2r7.06.46.4
Inventory3.45.85.95.84.13.93.6r4.07.612
Other current assets1.61.41.11.72.92.73.0r1.91.82.0
Current assets38372935356937r474979
Property, plant and equipment4.65.86.42.22.52.62.4r2.62.51.4
Right-of-use (leased) assets2.63.22.73.97.72.9r3.2r———
Goodwill0.90.90.90.90.90.90.9r0.90.90.9
Other intangible assets9.710110————0.00.0
Total assets57595247497844r535983
Accounts payable2.02.94.54.13.74.23.0r4.54.25.9
Debt due within a year0—01.67.40————
Current liabilities9.6141718211312r139.110
Long-term debt8.88.58.37.613210———
Lease liabilities (non-current)1.51.71.42.6—1.81.8r———
Total liabilities20273133464424r2526—
Retained earnings−403−398−397−389−370−337−307r−272−240−214
Shareholders' equity373321142.53420r27r3353
Total liabilities and equity57595247497844r535983
Shares outstanding3.9r3429128.5r9465575252
Cash-flow statement
Depreciation and amortization2.22.21.40.60.70.80.8r0.70.50.8
Share-based compensation1.81.30.90.30.90.55.0r4.47.2r10
Cash from operating activities−0.74.2−9.4−17r−34−30−27r−20−21r−12
Capital expenditure−0.5−1.0−0.3———————
Cash from investing activities−8.5−4.9−3.0−2.40.33.2−4.8r1315−1.6
Debt issued————0230———
Debt repaid—0−2.0−12−0.80————
Shares issued7.8101515——5.4220.1—
Cash from financing activities4.37.31116r−2.26321r22−2.20.1
Exchange-rate effect on cash0−0.0−0.0−0.0——————
Change in cash−5.06.7−1.1−3.2−3537−11r14−8.8−14
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Rockwell Medical, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Concentrate Products Sales$69 M100%
  • License Fees$0 M0.5%

Business segments

  • Reportable$69 M100%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Rockwell Medical, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.9 M
Mark Strobeck
Other top executives, average
$903 K
the CEO earned 2.1× this
$100 invested is now
$82
Rockwell Medical, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Mark Strobeck$1.9 M$1.1 M$903 K$82
2024Mark Strobeck$1.3 M$1.4 M$645 K$202
2023Mark Strobeck$1.1 M$1.8 M$427 K$187

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Rockwell Medical, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling

Delisting notice 1 · Directors and officers 3 · Material agreement 1 · Unregistered share sale 1 · Shareholder rights changed 1 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 10

Rockwell Medical, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Delisting notice8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Shareholder vote8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Rockwell Medical, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2018$22 MPrivate placement after listing$10 to $50 million1equitySEC
Oct 2014$15 MPrivate placement after listing$10 to $50 million1equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

FDA drug approvals: Rockwell Medical, Inc.#

3 approved applications held; 1 approvals and 0 new uses in 2020.

Approvals held
3
New molecular entities
0
New uses approved
0
efficacy supplements
Generics
0
3 new drugs, 0 biologics
Rockwell Medical, Inc.: latest FDA approvals
ApprovedDrugKind
2020-03-27Triferic AvnuFerric Pyrophosphate Citrate · NDA212860New drug (NDA)
2016-04-25TrifericFerric Pyrophosphate Citrate · NDA208551New drug (NDA)
2015-01-23TrifericFerric Pyrophosphate Citrate · NDA206317New drug (NDA)

Source: Drugs@FDA (openFDA). Approvals are listed under the application's current holder (ROCKWELL MEDICAL INC), so they follow acquisitions

Product recalls by Rockwell Medical, Inc.#

1 recalls since 2015, 139 units in the notices that give a number. Medical devices (FDA): 1.

Rockwell Medical, Inc.: product recalls
DateWhat and whyUnitsNotice
DriSate¿ Product Code DR-145 The acid concentrate powders and liquids are indicated for use in acute and chronic hemodialysis and to be used with the appropriate hemodialysis machine/monitor and bicarbonate concentrate.A subassembly component (dextrose bag) within this case product contained small amounts of sodium bicarbonate from a prior batch.Medical devicesClass II139Z-1869-2018

Source: NHTSA, CPSC and FDA recall notices. Recalls filed under a subsidiary with a different name may be missing. The number of recalls says nothing about their seriousness

How Rockwell Medical, Inc. compares in Pharmaceutical

  • Market cap$32 M · higher than 10% of 393
  • Revenue$69 M · higher than 18% of 324
  • Net margin-7.8% · higher than 20% of 313
  • Revenue growth-31.8% · higher than 6% of 107
  • Price / sales0.4× · lower than 94% of 219
  • Price / book0.9× · lower than 85% of 207
  • FCF yield-3.7% · higher than 26% of 69

Peer comparison · Pharmaceutical

CompanyMarket capP/ENet marginRev. growth
Rockwell Medical, Inc.🇺🇸$32 M—-7.8%-31.8%
Eli Lilly and Company🇺🇸$1.20 T43.4×31.9%+44.7%
Johnson & Johnson🇺🇸$652.5 B40.5×16.2%+6.0%
AbbVie Inc.🇺🇸$514.0 B49.7×15.7%+8.6%
Roche Holding AG🇨🇭$370.3 B29.1×19.0%—
Merck & Co., Inc.🇺🇸$359.8 B146.7×3.6%+1.3%
Novartis AG🇨🇭$286.8 B20.5×24.7%—
Amgen Inc.🇺🇸$249.2 B26.5×24.1%+9.9%
AstraZeneca PLC🇬🇧$242.6 B23.7×17.4%+8.6%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 16, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikipedia, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Rockwell Medical, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Rockwell Medical, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Rockwell Medical, Inc.? Suggest a correction